ACE and chronic kidney disease: The FIDELIO‐DKD trial indicated the cardio‐renal protective effects of the nsMRA finerenone, enrolling 5734 people with type 2 diabetes and CKD (eGFR ≥25 and ≤ 75 mL/min) and established on RAS inhibition with an ACE inhibitor or angiotensin type 1 receptor blocker.105